Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Participants With Relapsed/Refractory Multiple Myeloma

Next Previous
X
Search
Trial Profile

A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Participants With Relapsed/Refractory Multiple Myeloma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ISB 1442 (Primary)
  • Indications Acute myeloid leukaemia; Multiple myeloma; Precursor T-cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Ichnos Sciences

    • Most Recent Events

    • 05 Nov 2024 According to an Ichnos Glenmark Innovation media release, the company to present results from this trial at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, CA.
    • 12 Dec 2023 Initial results (n=10) of dose-escalation portion of this trial presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 09 Nov 2023 According to an Ichnos Sciences media release, data from this study have been selected for presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will be held December 9-12, 2023, in San Diego, California.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top